Recent efforts to target MYCN in pediatric brain tumors, including neuroblastomas, medulloblastomas, high-grade gliomas, atypical teratoid/rhabdoid tumors, ependymomas, and pineoblastomas, have faced significant challenges. Here, MYCN is linked to central nervous system cancer.